INM
InMed·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About INM
Inmed Pharmaceuticals Inc.
A leader in the research, development and manufacturing of rare cannabinoids
Suite 1445, 885 West Georgia St., Vancouver, British, Columbia, Canada V6C 3E8
--
InMed Pharmaceuticals Inc., was incorporated in British Columbia on May 19, 1981 under the British Columbia Business Companies Act. The Company is a pharmaceutical company that is developing a series of proprietary small molecule drug candidates that are priority signaling ligands for endogenous CB1 and CB2 receptors, as well as other receptor targets associated with human diseases. Through its R&D efforts, the company focuses on therapeutic areas with unmet medical needs, and its projects involve diseases such as Alzheimer's disease, dry age-related macular degeneration and epidermolysis bullosa. Together with its wholly-owned subsidiary BayMedica, LLC, InMed also develops proprietary manufacturing methods to produce and commercialize bulk rare cannabinoids as ingredients in multiple market segments, thereby maintaining its position in pharmaceutical innovation and cannabinoid-based technologies.
Company Financials
EPS
INM has released its 2025 Q4 earnings. EPS was reported at -1.2, versus the expected 0, missing expectations. The chart below visualizes how INM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
INM has released its 2026 Q1 earnings report, with revenue of 1.12M, reflecting a YoY change of -11.43%, and net profit of -1.73M, showing a YoY change of -2.92%. The Sankey diagram below clearly presents INM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
